Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

594 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical trial.
Bode BW, Buse JB, Fisher M, Garg SK, Marre M, Merker L, Renard E, Russell-Jones DL, Hansen CT, Rana A, Heller SR; BEGIN® Basal-Bolus Type 1 trial investigators. Bode BW, et al. Among authors: marre m. Diabet Med. 2013 Nov;30(11):1293-7. doi: 10.1111/dme.12243. Epub 2013 Jun 17. Diabet Med. 2013. PMID: 23710902 Free PMC article. Clinical Trial.
Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes.
Thomas MC, Woodward M, Neal B, Li Q, Pickering R, Marre M, Williams B, Perkovic V, Cooper ME, Zoungas S, Chalmers J, Hillis GS; ADVANCE Collaborative Group. Thomas MC, et al. Among authors: marre m. Diabetes Care. 2015 Oct;38(10):1891-7. doi: 10.2337/dc15-0925. Epub 2015 Aug 7. Diabetes Care. 2015. PMID: 26253728 Clinical Trial.
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB; LEADER Steering Committee; LEADER Trial Investigators. Marso SP, et al. N Engl J Med. 2016 Jul 28;375(4):311-22. doi: 10.1056/NEJMoa1603827. Epub 2016 Jun 13. N Engl J Med. 2016. PMID: 27295427 Free PMC article. Clinical Trial.
Insulin regimens and glycemic control in different parts of Europe over 4years after starting insulin in people with type 2 diabetes: Data from the CREDIT non-interventional study.
Blonde L, Marre M, Vincent M, Brette S, Pilorget V, Danchin N, Vespasiani G, Home P. Blonde L, et al. Among authors: marre m. Diabetes Res Clin Pract. 2017 Nov;133:150-158. doi: 10.1016/j.diabres.2017.08.016. Epub 2017 Aug 31. Diabetes Res Clin Pract. 2017. PMID: 28938142 Free article.
The Impact of Frailty on the Effectiveness and Safety of Intensive Glucose Control and Blood Pressure-Lowering Therapy for People With Type 2 Diabetes: Results From the ADVANCE Trial.
Nguyen TN, Harris K, Woodward M, Chalmers J, Cooper M, Hamet P, Harrap S, Heller S, MacMahon S, Mancia G, Marre M, Poulter N, Rogers A, Williams B, Zoungas S, Chow CK, Lindley RI. Nguyen TN, et al. Among authors: marre m. Diabetes Care. 2021 Jul;44(7):1622-1629. doi: 10.2337/dc20-2664. Epub 2021 May 25. Diabetes Care. 2021. PMID: 34035077 Free PMC article.
594 results